Oramed Pharmaceuticals (ORMP) Q1 2026 earnings summary

Executive summary

• Achieved net income of $38.3M for Q1 2026, a significant turnaround from a net loss of $7.6M in Q1 2025, driven by strong financial income and gains from investments and asset sales.

• Completed a strategic transaction with Lifeward, transferring the POD™ technology platform and receiving equity, warrants, and revenue-sharing rights.

• Continued portfolio optimization with new investments in real estate and financial instruments, and divestment of certain equity holdings.

Financial highlights

• Net income for Q1 2026 was $38.3M, compared to a net loss of $7.6M in Q1 2025.

• Financial income reached $44.8M, mainly from revaluation of Alpha Tau, Scilex, and Hapisga investments.

• Operating loss narrowed to $3.7M from $4.5M year-over-year, reflecting lower R&D and G&A expenses.

• Cash and cash equivalents decreased to $13.2M as of March 31, 2026, from $45.9M at year-end 2025.

• Paid $10.1M in dividends during the quarter.

Outlook and guidance

• Management expects to increase R&D activities and related expenses as it prepares for a revised Phase 3 trial of the oral insulin program through OraTech.

• Current cash resources and commitments are expected to support planned activities for at least the next 12 months.